ReviewNature reviews. Rheumatology2018
Rheumatic immune-related adverse events from cancer immunotherapy.
Review in Nature reviews. Rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Efficacy and safety of subcutaneous versus intravenous administration of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.Cancer immunology, immunotherapy : CII · 2021Pooled it
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Annals of the rheumatic diseases · 2021Guideline
- Management of immune checkpoint inhibitor-related rheumatic adverse events.Thoracic cancer · 2020Pooled it
- Tertiary lymphoid structures in gastrointestinal cancer: orchestrating tumour microenvironmental immune subcycles to elegantly amplify the cancer immunity cycle.Annals of medicine · 2026Review
- Immune Hallmarks of Recurrent Immune Checkpoint Inhibitor-Mediated Inflammatory Arthritis.Cancer immunology research · 2026Article
- Article
- Checkpoint inhibitors create rogue regulatory T cells.The Journal of clinical investigation · 2026Article
- Toward Precision Health in Autoimmunity and Immune-Related Adverse Events: The Autoantibody Reactome, Spatial Omics, and Multimodal Data Integration.Biomedicines · 2026Article
- Article
- HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion.Cell reports. Medicine · 2026Article
- Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.Scientific reports · 2026Article
- Bridging the Precision Gap in Rheumatoid Arthritis: Spatial Transcriptomics, Spatial Proteomics, and Artificial Intelligence in Precision Health.Biomedicines · 2026Review
- Targeting tumor-infiltrating regulatory T cells based on immunometabolism.Cancer biology & medicine · 2026Review
- Management Dilemma: Myeloperoxidase (MPO)-Positive Vasculitis in a Patient With Metastatic Malignant Melanoma.Cureus · 2026Article
- Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- The association of osteoarthritis with the risk of de novo inflammatory arthritis in patients receiving immune checkpoint inhibitors: a retrospective study.medRxiv : the preprint server for health sciences · 2026Article
- Organic Semiconducting Polymers for Cancer Sonodynamic Immunotherapy.Polymer science & technology (Washington, D.C.) · 2026Review
- Immune checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tislelizumab in advanced head and neck carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma.Frontiers in immunology · 2026Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.
Indexed as
Identifiers
30171203What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.